Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
Jennerex, Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today
Continue readingBayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Advanced Liver Cancer
WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international
Continue readingCardio Could Hold Key to Cancer Cure
AMSTERDAM, April 26, 2013 /PRNewswire/ -Regular exercise has been proven to reduce the chance of developing liver cancer in a world-first mice study that carries hope for patients at risk from hepatocellular carcinoma (HCC).(Logo
Continue readingGenomic Gains Coverage for DCIS
Genomic Health expands coverage with ductal carcinoma in situ (DCIS) diagnosis, effective May 8
Continue readingResearch and Markets: EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022
Research and Markets has announced the addition of the "EpiCast Report: Non-Small Cell Lung Cancer - Epidemiology Forecast to 2022" report to their offering
Continue readingRegular exercise reduces the risk of liver cancer
AMSTERDAM, Netherlands, April 28 (UPI) -- Swiss researchers say patients at risk from hepatocellular carcinoma -- the most common form of liver cancer -- may reduce their risk by regular exercise
Continue readingIsis Initiates ISIS-STAT3 Study
Isis Pharma announced the initiation of a phase Ib/IIa study on ISIS-STAT3
Continue readingNovel screening tests for liver cancer
( European Association for the Study of the Liver ) New data from two clinical trials presented today at the International Liver Congress 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma and cholangiocarcinoma using diagnostic urine tests
Continue readingGenomic Health and ECOG-ACRIN Cancer Research Group Announce Publication of Positive DCIS Validation Study in the ...
REDWOOD CITY, Calif. and PHILADELPHIA, May 2, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and the ECOG-ACRIN Cancer Research Group announced today that the Journal of the National Cancer Institute
Continue readingLpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
SAN DIEGO -- Lpath, Inc. , the industry leader in bioactive lipid-targeted therapeutics,has initiated dosing in a Phase 2a single-arm trial where ASONEP(TM) is being investigated as a treatment for renal
Continue reading


